Company profile
AIM ImmunoTech Inc.
AMEX: AIM · Healthcare · Biotechnology
#1047 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
36DFH 18DQ 57GM 37SS 54
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ operating margin, net margin
Methodology →Revenue TTM
$94.0k
Rev growth YoY (TTM)
-35.6%
Net income (FY)
-$14.0M
Employees
19
as of 2026-08-26
Market cap
$864.5k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$88.0k$88.0k2025
Net income-$14.0M-$14.0M2025
Operating income-$11.7M-$11.7M2025
Total assets$5.8M$5.8M2025
Liabilities$15.6M$15.6M2025
Equity-$9.8M-$9.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Clinical Treatment Programs - US100%
By geography
Not disclosed.
The read
What is AIM ImmunoTech Inc.’s revenue?
AIM ImmunoTech Inc. booked $88.0k in FY2025 revenue, contracting 48% year over year — slower than 81% of Healthcare companies we track, at a -15861.4% net margin.
Peers · Healthcare
Allied Corp.——Actinium Pharmaceuticals, Inc.28DCitius Pharmaceuticals, Inc.42DZecotek Photonics Inc.——Black Bird Biotech, Inc.——U.S. Stem Cell, Inc.——Key facts
CEOThomas K. Equels
SectorHealthcare
IndustryBiotechnology
HeadquartersOcala, FL
ExchangeAMEX: AIM
Employees19
IPO date1995-11-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.